Page last updated: 2024-12-06
ep 201
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
EP 201: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 61094 |
| CHEMBL ID | 1894251 |
| CHEBI ID | 82463 |
| SCHEMBL ID | 15554 |
| MeSH ID | M0061048 |
Synonyms (59)
| Synonym |
|---|
| wln: t36 botj f1 evo1-et36 botj f1 |
| ep 201 |
| unox epoxide 201 |
| 7-oxabicyclo[4.1.0]heptane-3-carboxylic acid, (4-methyl-7-oxabicyclo[4.1.0]hept-3-yl)methyl ester |
| 4,5-epoxy-2-methylcyclohexanecarboxylate |
| 3,4-epoxy-6-methylcyclohexanecarboxylate |
| mls002638023 , |
| 3,4-epoxy-6-methylcyclohexylmethyl) ester |
| nsc-7587 |
| cyclohexanecarboxylic acid,4-epoxy-6-methyl-, 3,4-epoxy-6-methylcyclohexylmethyl ester |
| nsc7587 |
| 7-oxabicyclo[4.1.0]heptane-3-carboxylic acid,(4-methyl-7-oxabicyclo[4.1.0]hept-3-yl)methyl ester |
| unox 201 |
| chissonox 201 |
| 3,4-epoxy-6-methylcyclohexane carboxylate |
| 141-37-7 |
| 6-methyl-3,4-epoxycyclohexanecarboxylate |
| 3,4'-epoxy-6'-methylcyclohexanecarboxylate |
| epoxide 201 |
| 3,4-epoxy-6-methylcyclomethyl 3,4-epoxy-6-methylcyclohexanecarboxylate |
| 3,4-epoxy-6-methylcyclohexenecarboxylic acid (3,4-epoxy-6-methylcyclohexylmethyl) ester |
| nsc 61273 |
| epoxide-201 |
| 3,4-epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanecarboxylate |
| 7-oxabicyclo(4.1.0)heptane-3-carboxylic acid, 4-methyl-, (4-methyl-7-oxabicyclo(4.1.0)hept-3-yl)methyl ester |
| 6-methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate |
| 3,4-epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate |
| 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate |
| 4,5-epoxy-2-methylcyclohexylmethyl-4,5-epoxy-2-methylcyclohexanecarboxylate |
| 4-methyl-7-oxabicyclo(4.1.0)heptane-3-carboxylic acid, (4-methyl-7-oxabicyclo(4.1.0)hept-3-yl)methyl ester |
| brn 0246264 |
| ccris 279 |
| nsc-61273 |
| nsc61273 |
| 7-oxabicyclo[4.1.0]heptane-3-carboxylic acid, 4-methyl-, 4-methyl-7-oxabicyclo-[4.1.0]heptyl methyl ester |
| NCIOPEN2_002731 |
| smr001547526 |
| 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclo-hexanecarboxylate |
| C19417 |
| HMS3091D23 |
| unii-v9q7uuz15u |
| v9q7uuz15u , |
| SCHEMBL15554 |
| CHEBI:82463 , |
| CHEMBL1894251 |
| 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate |
| J34.618G , |
| 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxy-late |
| 4,5-epoxy-2-methylcyclohexylmethyl 4,5-epoxy-2-methylcyclohexanecarboxylate |
| (4-methyl-7-oxabicyclo(4.1.0)hept-3-yl)methyl 4-methyl-7-oxabicyclo(4.1.0)heptane-3-carboxylate |
| 4-methyl-7-oxabicyclo(4.1.0)heptane-3-carboxylic acid= (4-methyl-7-oxabicyclo(4.1.0)heptan-3-yl)methyl ester |
| (3-methyl-7-oxabicyclo(4.1.0)heptan-4-yl)methyl 3-methyl-7-oxabicyclo(4.1.0)heptane-4-carboxylate |
| ep-201 |
| chisso nox-201 |
| 3,4-epoxy-6-methylcyclohexanecarboxylic acid (3,4-epoxy-6-methylcyclohexylmethyl) ester |
| Q27155960 |
| (4-methyl-7-oxabicyclo[4.1.0]heptan-3-yl)methyl 4-methyl-7-oxabicyclo[4.1.0]heptane-3-carboxylate |
| DTXSID90930968 |
| {4-methyl-7-oxabicyclo[4.1.0]heptan-3-yl}methyl 4-methyl-7-oxabicyclo[4.1.0]heptane-3-carboxylate |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| oxacycle | Any organic heterocyclic compound containing at least one ring oxygen atom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (4)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| USP1 protein, partial | Homo sapiens (human) | Potency | 0.2512 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| TDP1 protein | Homo sapiens (human) | Potency | 16.3601 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 19.9526 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (11)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 61.02
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (61.02) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||